• Event Details
• Agenda
• CE Information

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
Upon completion of this activity, participants should be able to

• Customize the use of induction, consolidation and maintenance therapeutic approaches for MM in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
• Appreciate available clinical trial data documenting the efficacy of monoclonal antibody therapy directed at CD38 as a component of induction therapy, and effectively identify whether and how this strategy should be integrated into the clinical care of patients eligible or ineligible for stem cell transplant.
• Recognize published research data validating the use of minimal residual disease (MRD) status as a mechanism to assess response to active therapy and to identify disease recurrence, and use this information to determine the potential role of MRD assays in the protocol and off-protocol management of MM.
• Consider published research findings and other clinical factors in the best-practice selection, sequencing or combination of available therapies in the nonresearch care of patients with relapsed/refractory MM.
• Develop an understanding of the mechanism of action of and available data with recently FDA-approved novel therapies to facilitate their integration into MM management algorithms.
• Appreciate available data documenting the activity of chimeric antigen receptor T-cell therapy, bispecific T-cell engagers and antibody-drug conjugates designed to target B-cell maturation antigen, and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches.
• Assess ongoing clinical trials evaluating novel investigational approaches for MM, and obtain consent from appropriate patients for study participation.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Fonseca — Advisory Committee: Adaptive Biotechnologies Corporation, ONCOtracker Inc; Consulting Agreements: AbbVie Inc, Aduro Biotech, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Merck, Novartis, ONCOtracker Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology. Dr Landgren — Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc; Contracted Research: Amgen Inc, Janssen Biotech Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc, Merck, Takeda Oncology, Theradex Oncology. Dr Munshi — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc, BeiGene, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep. Dr Orlowski — Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital LLC, FORMA Therapeutics, Genzyme Corporation, GlaxoSmithKline, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Molecular Partners, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier, Takeda Pharmaceuticals North America Inc; Consulting Agreement: STATinMED; Contracted Research: BioTheryX Inc, CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals North America Inc; Ownership Interest: Asylia Therapeutics Inc (founder, patents, equity). Dr Stadtmauer — Consulting Agreements: Amgen Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Sanofi Genzyme, Takeda Oncology.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme and Takeda Oncology.